Cargando…

Thyroid Bethesda Category AUS/FLUS in Our Microscopes: Three-Year-Experience and Cyto-Histological Correlation

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) introduced a new category: Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) comprising of heterogenous lesions with a lesser degree of atypia. Its routine use is a bit controversial. The stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huhtamella, Roope, Kholová, Ivana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895794/ https://www.ncbi.nlm.nih.gov/pubmed/31661800 http://dx.doi.org/10.3390/cancers11111670

Ejemplares similares

The Prediction of Malignancy Risk in Thyroid Nodules Classified as Bethesda System Category III (AUS/FLUS) and the Role of Ultrasound Finding for Prediction of Malignancy Risk
por: Alshahrani, Awad S, et al.
Publicado: (2021)

Thyroid Bethesda Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS): A Heterogenous Group
por: Maity, Priyanka, et al.
Publicado: (2019)

Editorial: Subclassification of AUS/FLUS category for thyroid nodules: trials and evidence-based clinical management
por: Bayraktaroğlu, Taner, et al.
Publicado: (2023)

Diagnostic Thyroidectomy May Be Preferable in Patients With Suspicious Ultrasonography Features After Cytopathology Diagnosis of AUS/FLUS in the Bethesda System
por: Lee, Yong Sang, et al.
Publicado: (2015)

Clinicopathological factors increased the risk of malignancy in thyroid nodules with atypical or follicular lesions of undetermined significance (AUS/FLUS) risk factor of malignancy in thyroid nodule with AUS/FLUS
por: Hong, In Ki, et al.
Publicado: (2016)

Triage of patients with AUS/FLUS on thyroid cytopathology: effectiveness of the multimodal diagnostic techniques
por: Kim, Tae Hyuk, et al.
Publicado: (2016)

Cyto-Histopathological Correlations in Pathology Diagnostics
por: Kholová, Ivana
Publicado: (2022)

Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis
por: Kaliszewski, Krzysztof, et al.
Publicado: (2022)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study
por: Hathi, Kalpesh, et al.
Publicado: (2021)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Does the Bethesda category predict aggressive features in differentiated thyroid cancer?
por: Lima, Ana Rafaela Lopes Reis, et al.
Publicado: (2019)

The Diagnostic Performance of Thyroid US in Each Category of the Bethesda System for Reporting Thyroid Cytopathology
por: Park, So Yoon, et al.
Publicado: (2016)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

Associations between Bethesda categories and tumor characteristics of conventional papillary thyroid carcinoma
por: Park, Vivian Youngjean, et al.
Publicado: (2018)

Cytomorphologic features distinguishing Bethesda category IV thyroid lesions from parathyroid
por: Sung, Simon, et al.
Publicado: (2017)

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAF(V600E) Mutation-Negative Nodules?
por: Yoon, Jung Hyun, et al.
Publicado: (2015)

Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature
por: Alshaikh, Safa, et al.
Publicado: (2018)

Intraoperative frozen section can be reduced in thyroid nodules classified as Bethesda categories V and VI
por: Huang, Jing, et al.
Publicado: (2017)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
por: Zahid, Adnan, et al.
Publicado: (2021)

Surgical Outcome and Malignant Risk Factors in Patients With Thyroid Nodule Classified as Bethesda Category III
por: Huang, Jianhao, et al.
Publicado: (2021)

Thyroid Cancer Detection Rate and Associated Risk Factors in Patients with Thyroid Nodules Classified As Bethesda Category III
por: Mileva, Magdalena, et al.
Publicado: (2018)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

The Bethesda System thyroid diagnostic categories in the African-American population in conjunction with surgical pathology follow-up
por: Archuletta, Pamela Anne, et al.
Publicado: (2012)

Histopathological Review of Diagnostic Categories of the Bethesda System for Reporting Thyroid Cytopathology – An Institutional Experience of 5 Years
por: Upadhyaya, Paricha, et al.
Publicado: (2019)

Birds, Pigs, and People: The Rise of Pandemic Flus
por: Walters, Mark Jerome
Publicado: (2014)

Third CMAS (CytoJournal Monograph/Atlas Series) titled “Uterine Cervix Cancer and The Bethesda System”
por: Shidham, Vinod B., et al.
Publicado: (2022)

A study of malignancy rates in different diagnostic categories of the Bethesda system for reporting thyroid cytopathology: An institutional experience
por: Arul, P., et al.
Publicado: (2015)

Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
por: Yoo, Won Sang, et al.
Publicado: (2020)

Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile
por: Kholová, Ivana, et al.
Publicado: (2022)

Solid/trabecular subtype of papillary thyroid carcinoma on cytology with focal differentiated high-grade thyroid carcinoma on histology: a cyto-histologic correlation
por: Rath, Ashutosh, et al.
Publicado: (2023)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center
por: Godoi Cavalheiro, Beatriz, et al.
Publicado: (2017)

Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules
por: Jin, Xiaobing, et al.
Publicado: (2022)

Cytomorphological Categorization of Thyroid Lesions according to The Bethesda System for Reporting Thyroid Cytology and Correlation with their Histological Outcome: An Indian Oncology Centre Experience
por: Kamboj, Meenakshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o40c9qlpud7fs75amomgs0jdhm